{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:45:32Z","timestamp":1790718332611,"version":"4.1.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","award":["2110-5191"],"award-info":[{"award-number":["2110-5191"]}],"id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) imposes a substantial health and economic burden on many populations and countries, but lack of funding has significantly contributed to several countries falling short of global TB reduction targets. Furthermore, existing assessments of the economic impact of TB do not capture the impacts on productivity and economic growth or the pathways by which epidemiology, demography, and the economy interact. Evidence is needed to answer how investment in treatment and control measures may help to mitigate the twin Indian health and macroeconomic burdens of TB over the coming decades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We develop a fully integrated dynamic macroeconomic-health-demographic simulation model for India, the country with the largest national TB burden, and use it to estimate the macroeconomic return to investment in TB treatment.<\/jats:p>\n                    <jats:p>Our estimated results indicate that, over 2021 to 2040, the health and macroeconomic burdens of TB in India will include over 62.4m incident cases, 8.1m TB-related deaths and a cumulative gross domestic product (GDP) loss of US$146.4bn. Low-income households will bear larger health and relative economic burdens while larger absolute economic burdens will fall on high-income households. Achieving the World Health Organisation\u2019s End TB target of 90% case detection could reduce clinical and demographic disease burdens by 75% to 89% and reduce the macroeconomic burden by US$120.2bn. Developing a 95% effective pan-TB treatment regimen would reduce the same burdens by 25% to 31% and US$35.3bn, respectively, while less effective but immediately achievable scaling-up of existing treatment regimens would reduce burdens by 20% to 25% and US$28.4bn, respectively. If an increase in case detection to 90% could be combined with 95% effective pan-TB treatment, it could reduce clinical and demographic disease burdens by 78% to 91% and reduce the macroeconomic burden by US$124.2bn.<\/jats:p>\n                    <jats:p>In order to develop this complex integrated model framework, some aspects of the epidemiological model were simplified such that the model does not capture, for example, separate modelling of drug susceptible and multidrug-resistant (MDR) cases or separate public\/private healthcare provision. However, future iterations of the model could address these limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, we find that even our least effective, but most accessible, revised TB treatment regimen has the potential to generate US$28bn in GDP gains. Clearly, the economic gains of increasing case detection rates and implementing improved TB treatment regimens hinges on both the feasibility and timeframe over which they can be achieved in practice. Nevertheless, the revised TB treatment regimen is readily accessible, and our results therefore demonstrate that there is room for undertaking substantial additional investment in control and treatment of TB in India, in order to reduce the suffering of TB patients while maintaining acceptable provision of resourcing elsewhere in the Indian economy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004491","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:22:41Z","timestamp":1734009761000},"page":"e1004491","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Estimating the health and macroeconomic burdens of tuberculosis in India, 2021\u20132040: A fully integrated modelling study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7556-0016","authenticated-orcid":true,"given":"Marcus R.","family":"Keogh-Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-534X","authenticated-orcid":true,"given":"Tom","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4233-9080","authenticated-orcid":true,"given":"Sedona","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vassall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-458X","authenticated-orcid":true,"given":"Henning Tarp","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"pmed.1004491.ref001","doi-asserted-by":"crossref","unstructured":"GBD Diseases and Injuries Collaborators 2020, Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u20131222. DOI: 10.1016\/S0140-6736(20)30925-9","DOI":"10.1016\/S0140-6736(20)30925-9"},{"issue":"10","key":"pmed.1004491.ref002","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1016\/S2214-109X(21)00299-0","article-title":"Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis","volume":"9","author":"S Silva","year":"2021","journal-title":"Lancet Glob Health"},{"key":"pmed.1004491.ref003","volume-title":"Global tuberculosis report 2022","author":"WHO","year":"2022"},{"key":"pmed.1004491.ref004","doi-asserted-by":"crossref","first-page":"100435","DOI":"10.1016\/j.ssmph.2019.100435","article-title":"International trade, dietary change, and cardiovascular disease health outcomes: Import tariff reform using an integrated macroeconomic, environmental and health modelling framework for Thailand","volume":"9","author":"HT Jensen","year":"2019","journal-title":"SSM Popul Health"},{"issue":"11","key":"pmed.1004491.ref005","doi-asserted-by":"crossref","first-page":"e1123","DOI":"10.1016\/S2214-109X(17)30341-8","article-title":"Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study","volume":"5","author":"S Verguet","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"9979","key":"pmed.1004491.ref006","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new end TB strategy","volume":"385","author":"M Uplekar","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"pmed.1004491.ref007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.5588\/ijtld.17.0835","article-title":"Global tuberculosis targets and milestones set for 2016\u20132035: definition and rationale","volume":"22","author":"K Floyd","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"pmed.1004491.ref008","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1473-3099(20)30124-9","article-title":"Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000\u201317: a financial modelling study","volume":"20","author":"S Yanfang","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004491.ref009","article-title":"The Health and Economic Benefits Possible with Novel Tuberculosis Vaccines\u2013A Modeling Study in India and Indonesia","author":"S Silva","year":"2021","journal-title":"Res Sq Pre-print"},{"issue":"1","key":"pmed.1004491.ref010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1257\/jel.20201642","article-title":"Modern infectious diseases: macroeconomic impacts and policy responses","volume":"60","author":"DE Bloom","year":"2022","journal-title":"J Econ Lit"},{"key":"pmed.1004491.ref011","volume-title":"WHO guide to identifying the economic consequences of disease and injury","author":"WHO","year":"2009"},{"issue":"5","key":"pmed.1004491.ref012","doi-asserted-by":"crossref","first-page":"e96389","DOI":"10.1371\/journal.pone.0096389","article-title":"Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis","volume":"9","author":"MO Fofana","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"pmed.1004491.ref013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12916-016-0608-4","article-title":"TIME Impact\u2013a new user-friendly tuberculosis (TB) model to inform TB policy decisions","volume":"14","author":"RMGJ Houben","year":"2016","journal-title":"BMC Med"},{"issue":"1","key":"pmed.1004491.ref014","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12916-020-01651-5","article-title":"The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region: a modelling approach","volume":"18","author":"S Mandal","year":"2020","journal-title":"BMC Med"},{"issue":"11","key":"pmed.1004491.ref015","doi-asserted-by":"crossref","first-page":"e1001347","DOI":"10.1371\/journal.pmed.1001347","article-title":"Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB\/RIF: A Dynamic Simulation and Economic Evaluation","volume":"9","author":"NA Menzies","year":"2012","journal-title":"PLoS Med"},{"key":"pmed.1004491.ref016","unstructured":"GOV.UK. HMRC\u2019s CGE model documentation. Technical documents and research based on HM Revenue & Customs (HMRC) CGE model, 2013. Available from: https:\/\/www.gov.uk\/government\/publications\/computable-general-equilibrium-cge-modelling (accessed 28 Oct 2024)."},{"key":"pmed.1004491.ref017","first-page":"6621","article-title":"International trade, dietary change, and TB control in India: Application of a fully-integrated macroeconomic-epidemiological model framework","author":"HT Jensen","year":"2023","journal-title":"GTAP Resource"},{"key":"pmed.1004491.ref018","unstructured":"L\u00f6fgren H, Lee Harris R, Robinson S. A Standard Computable General Equilibrium (CGE) Model in GAMS. Microcomputers and Policy Research 5, Washington DC: International Food Policy Research Institute. 2002. Available from: https:\/\/ebrary.ifpri.org\/digital\/collection\/p15738coll2\/id\/74766 (accessed 26 Jul 2021)."},{"issue":"1","key":"pmed.1004491.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21642\/JGEA.040101AF","article-title":"The GTAP Data Base: Version 10","volume":"4","author":"A Aguiar","year":"2019","journal-title":"J Glob Econ Anal"},{"issue":"10","key":"pmed.1004491.ref020","first-page":"3150","volume":"105","author":"RC Feenstra","year":"2015","journal-title":"The Next Generation of the Penn World Table Am Econ Rev"},{"key":"pmed.1004491.ref021","unstructured":"NSSO. National Sample Survey (NSS) 68th round 2011\u201312, in Ministry of Statistics & Programme Implementation. National Sample Survey Office, Government of India, 2018. Available from: https:\/\/microdata.gov.in\/nada43\/index.php\/catalog\/127\/study-description (accessed 15 Apr 2022)."},{"key":"pmed.1004491.ref022","unstructured":"WB. World Development Indicators (WDI) database (Electronic data). 2021. Washington DC: World Bank. Available from: https:\/\/databank.worldbank.org\/source\/world-development-indicators (accessed 26 Jul 2021)."},{"key":"pmed.1004491.ref023","unstructured":"UN. World Population Prospects, the 2019 Revision (Electronic data). 2019. New York: United Nations. Available from: http:\/\/esa.un.org\/unpd\/wpp\/index.htm (accessed 11 Jun 2020)."},{"issue":"3","key":"pmed.1004491.ref024","doi-asserted-by":"crossref","first-page":"e00498","DOI":"10.1128\/AAC.00498-16","article-title":"A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis","volume":"61","author":"MO Fofana","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"pmed.1004491.ref025","unstructured":"IIPS. National Family Health Survey (NFHS-4), 2015\u201316. Mumbai: International Institute for Population Sciences (IIPS). 2017. Available from: https:\/\/dhsprogram.com\/publications\/publication-fr339-dhs-final-reports.cfm (accessed 28 Oct 2024)."},{"issue":"1","key":"pmed.1004491.ref026","doi-asserted-by":"crossref","first-page":"e47533","DOI":"10.1371\/journal.pone.0047533","article-title":"Tuberculosis and poverty: why are the poor at greater risk in India?","volume":"7","author":"O Oxlade","year":"2012","journal-title":"PLoS ONE"},{"key":"pmed.1004491.ref027","volume-title":"Data provided by countries to WHO and estimates of TB burden generated by WHO for the Global Tuberculosis Report, in Global Tuberculosis Programme (Electronic Data)","author":"WHO","year":"2022"},{"key":"pmed.1004491.ref028","volume-title":"Tuberculosis Profile: India","author":"WHO","year":"2021"},{"key":"pmed.1004491.ref029","article-title":"Value TB Dataset: costs per intervention (Electronic Data)","author":"S Sweeney","year":"2021","journal-title":"Harvard Dataverse"},{"issue":"3","key":"pmed.1004491.ref030","doi-asserted-by":"crossref","first-page":"e0230808","DOI":"10.1371\/journal.pone.0230808","article-title":"The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis","volume":"15","author":"N Arinaminpathy","year":"2020","journal-title":"PLoS ONE"},{"key":"pmed.1004491.ref031","volume-title":"Target regimen profiles for TB treatment: candidates: rifampicin-susceptible, rifampicinresistant and pan-TB treatment regimens","author":"WHO","year":"2016"},{"key":"pmed.1004491.ref032","volume-title":"Global tuberculosis report 2021","author":"WHO","year":"2021"},{"key":"pmed.1004491.ref033","volume-title":"The end TB strategy","author":"WHO","year":"2015"},{"key":"pmed.1004491.ref034","unstructured":"RNTCP. National Strategic Plan for Tuberculosis Elimination 2017\u20132025. Revised National Tuberculosis Control Programme, Central TB Division, Ministry of Health with Family Welfare, Nirman Bhavan, New Delhi, 2017. Available from: https:\/\/tbcindia-wp.azurewebsites.net\/national-strategic-plan-2017-2025-for-tb-elimination-in-india\/ (accessed 28 Oct 2024)."},{"issue":"3","key":"pmed.1004491.ref035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5588\/pha.20.0017","article-title":"How much do Indians pay for tuberculosis treatment? A cost analysis","volume":"10","author":"P Sinha","year":"2020","journal-title":"Public Health Action"},{"key":"pmed.1004491.ref036","unstructured":"TAG. Stop TB Partnership. Tuberculosis research funding trends 2005\u20132020. New York: Treatment Action Group, 2021. Available from: https:\/\/www.stoptb.org\/tuberculosis-research-funding-trends-2005-2021-0 (accessed 28 Oct 2024)."},{"issue":"12","key":"pmed.1004491.ref037","doi-asserted-by":"crossref","first-page":"e1679","DOI":"10.1016\/S2214-109X(21)00367-3","article-title":"Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae","volume":"9","author":"NA Menzies","year":"2021","journal-title":"Lancet Glob Health"},{"key":"pmed.1004491.ref038","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.foodpol.2018.12.003","article-title":"Palm oil and dietary change: application of an integrated macroeconomic, environmental, demographic, and health modelling framework for Thailand","volume":"83","author":"HT Jensen","year":"2019","journal-title":"Food Policy"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:22:58Z","timestamp":1734009778000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004491"}},"subtitle":[],"editor":[{"given":"Amitabh Bipin","family":"Suthar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004491","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}